The quest for a fully immunogenic vaccine against influenzaH5N1 viruses has gone on for more than 10 years, since thisfamily of potentially pandemic viruses emerged as a cause ofhuman disease in Hong Kong in 1997. H5N1 has caused 381 humancases of influenza, with a mortality rate exceeding 60%. H5strains have now been found in birds throughout much of theworld (though not yet in the Americas), and human illness hasoccurred in 14 countries throughout Asia and in northern Africa.1The much-feared rapid spread through and between communities,however, has not occurred. Aside from small . . . [Full Text of this Article]
Source Information
Dr. Wright is a professor of pediatrics at Dartmouth Medical School, Hanover, NH.
This article has been cited by other articles:
Khazeni, N., Bravata, D. M., Holty, J.-E. C., Uyeki, T. M., Stave, C. D., Gould, M. K.
(2009). Systematic Review: Safety and Efficacy of Extended-Duration Antiviral Chemoprophylaxis Against Pandemic and Seasonal Influenza. ANN INTERN MED
151: 464-473
[Abstract][Full Text]
Khazeni, N., Hutton, D. W., Garber, A. M., Owens, D. K.
(2009). Effectiveness and Cost-Effectiveness of Expanded Antiviral Prophylaxis and Adjuvanted Vaccination Strategies for an Influenza A (H5N1) Pandemic. ANN INTERN MED
0: 0000605-200912150-00156v1-E-156
[Abstract][Full Text]
Rao, S. S., Styles, D., Kong, W., Andrews, C., Gorres, J. P., Nabel, G. J.
(2009). A gene-based avian influenza vaccine in poultry. Poult. Sci.
88: 860-866
[Abstract][Full Text]
Glezen, W. P.
(2008). Prevention and Treatment of Seasonal Influenza. NEJM
359: 2579-2585
[Full Text]
Previous
